<DOC>
	<DOCNO>NCT00186888</DOCNO>
	<brief_summary>Retinoblastoma childhood cancer affect retina eye . The retina light sensitive layer tissue line back eyeball ; send visual message optic nerve brain . When one eye affect , know unilateral retinoblastoma eye affect , call bilateral retinoblastoma . Treatment retinoblastoma individualize patient base form stage disease ( inside eye move outside ) . The main goal always cure cancer , save life child . Treatments also design hope save vision , completely destroy tumor . Therapies may involve surgery , chemotherapy , radiation , treatment call focal treatment . Focal treatment may laser therapy , freezing , heat treatment mean shrink kill tumor . In study , researcher want investigate different participant respond different therapy individualize specifically . Participants divide three main group , depend whether disease unilateral bilateral , stage disease . One main objective study investigate advanced tumor child bilateral disease respond new combination chemotherapy topotecan vincristine , G-CSF support . In order improve result , child advance disease may receive carboplatin chemotherapy give around eye time receive topotecan vein . Also , child retinoblastoma diagnose early life vision may significantly impair , study investigate child develop brain adjusts compensate visual deficit . Finally , study also investigate biology retinoblastoma , order understand well cancer develop .</brief_summary>
	<brief_title>Study Treatment Patients With Cancer Eye -Retinoblastoma</brief_title>
	<detailed_description>This study determine follow : PRIMARY OBJECTIVE : - To estimate ocular survival event-free survival bilateral disease patient advance intraocular retinoblastoma either eye ( R-E IV-V ) respond vincristine/topotecan window , alternate cycle vincristine carboplatin vincristine , topotecan , periocular carboplatin , intensive focal treatment . SECONDARY OBJECTIVES : - To estimate ocular survival eye event-free survival eye bilateral disease patient advance intraocular retinoblastoma either eye ( R-E IV-V ) respond vincristine/topotecan window , alternate cycle vincristine carboplatin vincristine , topotecan , periocular carboplatin , intensive focal treatment . - To estimate ocular survival event free survival patient advance intraocular retinoblastoma ( R-E IV-V ) respond vincristine/topotecan window , combination vincristine , carboplatin , etoposide , periocular carboplatin , intensive focal treatment . - To estimate ocular survival event free survival eye patient advance intraocular retinoblastoma ( R-E IV-V ) respond vincristine/topotecan window , combination vincristine , carboplatin , etoposide , periocular carboplatin , intensive focal treatment . - To estimate ocular survival event-free survival patient early stage intraocular retinoblastoma ( R-E I-III ) vincristine carboplatin intensive focal treatment . - To estimate ocular survival eye event-free survival eye patient early stage intraocular retinoblastoma ( R-E I-III ) vincristine carboplatin intensive focal treatment . - To estimate response rate early stage eye ( R-E I-III ) patient contralateral advanced disease treat vincristine topotecan . - To estimate ocular survival event-free survival early stage eye ( R-E I-III ) patient contralateral advanced disease treat vincristine topotecan . - To describe outcome intraocular retinoblastoma respect new International Classification Intraocular Retinoblastoma AJCC . - To describe primary visual cortex function patient unilateral bilateral retinoblastoma . - To describe cognitive , adaptive , social/emotional development child retinoblastoma . - To describe change pineal gland treatment patient bilateral retinoblastoma . - To assess relation CYP3A4/5 genotype pharmacokinetics pharmacodynamics topotecan . - To assess relation ABCG2 genotype pharmacokinetics pharmacodynamics topotecan . - To determine carboplatin produce change cochlear function detectable measurement otoacoustic emission . - To evaluate need feasibility start early intervention support first year diagnosis retinoblastoma . EXPLORATORY OBJECTIVES : - To provide insight molecular pathogenesis retinoblastoma . - To describe incidence type germline mutation RB gene patient retinoblastoma .</detailed_description>
	<mesh_term>Retinoblastoma</mesh_term>
	<mesh_term>Eye Neoplasms</mesh_term>
	<mesh_term>Retinal Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Must newly diagnose intraocular retinoblastoma , previously untreated . Patients previously diagnose unilateral retinoblastoma treat surgically ( focal therapy ) , develop asynchronous involvement contralateral eye , eligible study . Must life expectancy least 8 week . Must Performance Status ( ECOG ) 02 . Patients must adequate liver function , define bilirubin less equal 3 x normal , SGOT SGPT less equal 3x normal . Patients must adequate renal function define serum creatinine less equal 3x normal age . Legal guardian must sign informed consent indicate aware study , possible benefit , toxic side effect . Legal guardian give copy consent form . Previously treat patient Presence metastatic disease orbital involvement Patients must invasive infection time protocol entry .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Cancer Eye</keyword>
	<keyword>Eye Enucleation</keyword>
</DOC>